Abstract
About one of five patients with coronary artery disease (CAD) suffers from previously unknown, predominantly postprandial type 2 diabetes. In the process of atherogenesis and the subsequent increased cardiovascular mortality of diabetic patients, endothelial dysfunction is suspected to play an important role, and it is observed in diabetic as well as insulin-resistant states. Thus, the aim of our study was to investigate the effect of pioglitazone on endothelial dysfunction, insulin sensitivity, and glucose control in newly detected type 2 diabetic patients with CAD. We investigated 42 patients (39 men and 3 women, age 60.25 +/- 7.5 years, HbA1c 6.1 +/- 0.5%) with manifest CAD and newly detected type 2 diabetes. A randomized, double-blind, placebo-controlled, parallel study with pioglitazone (30 mg/day for 12 weeks) was performed. At study entry and end, we performed an oral glucose tolerance test and measurements of endothelial dysfunction by photoplethysmographic pulse wave analysis. Endothelial dysfunction was severely impaired at baseline in both groups. After 12 weeks, endothelial dysfunction was significantly better in the pioglitazone group (change of reflection index 6.5 +/- 5.1 vs. 1.6 +/- 2.9%, P = 0.002) compared wit...Continue Reading
Citations
Apr 26, 2008·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Jochen WöhrleThorsten Nusser
Nov 24, 2007·Diabetes, Obesity & Metabolism·D TousoulisC Stefanadis
Jul 21, 2009·Diabetes, Obesity & Metabolism·R ChapellC M Alexander
Jul 2, 2010·Diabetes, Obesity & Metabolism·C E QuinnG E McVeigh
Jul 19, 2006·International Journal of Clinical Practice·B J Goldstein
Aug 21, 2009·International Journal of Clinical Practice·M Fisher
Sep 1, 2007·PLoS Medicine·Debbie A LawlorGeorge Davey Smith
Jul 21, 2007·Endocrine Journal·Hiroshi MaegawaAtsunori Kashiwagi
May 9, 2013·Herz·Q ZhuJ Liu
May 18, 2013·Hospital Practice·Ralph A DefronzoJoel J Schnure
Jun 7, 2011·Expert Opinion on Pharmacotherapy·Thomas ForstAndreas Pfützner
Jan 29, 2008·Expert Opinion on Pharmacotherapy·Sheila A Doggrell
Jun 28, 2011·Primary Care Diabetes·Dana E KingCharles J Everett
Jun 26, 2007·Atherosclerosis·T ForstA Pfützner
Jul 20, 2007·Progress in Lipid Research·Nikolaus Marx, Daniel Walcher
Jun 6, 2009·International Journal of Clinical Practice·G Schernthaner
Nov 9, 2007·Diabetes/metabolism Research and Reviews·Antonio Ceriello
Nov 29, 2012·British Journal of Pharmacology·Fergus P McCarthySarah K Walsh
Feb 21, 2009·Journal of the American College of Cardiology·Heinrich R Schelbert
Jan 3, 2009·International Journal of Cardiology·Sabine PerlThomas C Wascher
Jan 13, 2009·Atherosclerosis·Katerina PapathanassiouLampros K Michalis
Dec 15, 2015·Diabetes, Obesity & Metabolism·A O StirbanM Herz
Oct 14, 2016·Trials·Norbert J TripoltHarald Sourij
Oct 22, 2016·Clinical Hemorheology and Microcirculation·Maria das Graças Coelho de SouzaEliete Bouskela
Aug 19, 2007·Journal of Cardiovascular Pharmacology·Eyal Leibovitz, Ernesto L Schiffrin
Feb 2, 2019·Frontiers in Physiology·João S TeodoroCarlos M Palmeira